Bio-Rad, Illumina Partner Tuesday, January 12, 2016 Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.First Insurance Coverage of NGS and Proteomic Diagnostic Platform Tuesday, January 12, 2016 With this announcement next-generation sequencing and precision medicine has evolved from research to the clinical cancer setting.Illumina Launches Cancer Screening Company Monday, January 11, 2016 Formation of GRAIL seen as a significant development in the war on cancer. Pfizer, Adaptive Biotechnologies Collaborate Monday, January 11, 2016 Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Milestone Resource in Wheat Research Now Available for Download Friday, January 08, 2016 Leading on from The Genome Analysis Centre’s (TGAC) previous announcement of their new bread wheat genome assembly, the landmark resource is now publically available to download at the European Bioinformatics Institute’s (EMBL-EBI) Ensembl database for full analysis.NRGene, Illumina Partner Thursday, January 07, 2016 NRGene has signed a co-marketing agreement with Illumina to promote NRGene’s proprietary de novo assembly informatics solution exclusively using Illumina sequencing technology.
Signal Genetics, MD Anderson Partner Thursday, January 07, 2016 200 patient study designed to advance signal genetics' MyPRS® assay.Applied Maths Joins the bioMérieux Family Wednesday, January 06, 2016 bioMérieux, a world leader in the field of in vitro diagnostics, today announced the acquisition of Applied Maths, a company that develops state-of-the-art software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data. Tracing a Cellular Family Tree Wednesday, January 06, 2016 New technique allows tracking of gene expression over generations of cells as they specialize.